Wiwik Agustina, Shofia Maharani Khoirun Nisa, Faidatul Chasanah

Diabetic Foot Exercises Can Reduce Neuropathy Degree in Type II Diabetes Mellitus (DM) Patients

Introduction

Diabetic foot exercises can reduce neuropathy degree in type ii diabetes mellitus (dm) patients. Discover how diabetic foot exercises (DFE) significantly reduce the degree of neuropathy in Type II Diabetes Mellitus (DM) patients. A vital non-pharmacological therapy for nerve damage.

Abstract

Neuropathy is nerve damage that occurs mainly in the feet and hands on diabetes mellitus (DM) patients. High blood sugar degree over a long period of time will cause complications, one of which is damage to small blood vessels (microvasculature) such as diabetic neuropathy with an incidence of 45.6%. Diabetic foot exercise (DFE) is a non-pharmacological therapy to overcome this. This study aims to determine the difference in the degree of neuropathy in type II DM patients between before and after receiving DFE therapy. The inquire about plan utilized  a Pre-Experiment Group Pretest-Posttest Plan  with a population of 105 individuals  and a sample of 26 individuals decided  through Quota Sampling. The investigate instrument utilizing the Neuropathy System Score (NSS) questionnaire. Information were analyzed utilizing the Wilcoxon Sign Rank Test. The results of this reserach stated that the average degree of neuropathy for the group before DFE therapy = 6.5000 (moderate) and after = 4.4615 (mild). DFE therapy had a significant effect on reducing the degree of neuropathy in respondents (P-value = 0.000). Thus, DFE therapy can be recommended to be applied to type II DM patients as a complementary therapy that can help reduce the degree of neuropathy.

Review

This study addresses a highly relevant and critical complication of Type II Diabetes Mellitus: diabetic neuropathy. The abstract clearly articulates its objective to evaluate the impact of diabetic foot exercises (DFE) on neuropathy degree, presenting DFE as a promising non-pharmacological intervention. The reported findings are compelling, indicating a statistically significant reduction in neuropathy degree from "moderate" to "mild" after DFE therapy (P-value = 0.000). This positive outcome suggests DFE could be a valuable complementary strategy in managing this debilitating condition, and the clear articulation of the problem and the initial positive results represent a strong foundation for this preliminary investigation. From a methodological perspective, the study employed a Pre-Experiment Group Pretest-Posttest Plan, which is suitable for initial explorations but inherently limited in establishing definitive causality due to the absence of a control group. The sample size of 26 individuals, chosen via Quota Sampling from a population of 105, is somewhat modest, potentially limiting the broad generalizability of the findings. Nevertheless, the statistical analysis using the Wilcoxon Sign Rank Test is appropriate for paired, non-normally distributed data, which is often characteristic of neuropathy scores. The utilization of the Neuropathy System Score (NSS) questionnaire provides a standardized and quantifiable measure of neuropathy, enhancing the study's objectivity, though clearer, more formal phrasing would benefit the full manuscript (e.g., "The inquire about plan utilized" could be refined). The conclusion that DFE therapy significantly reduces the degree of neuropathy is a promising one, positioning it as a potentially valuable complementary therapy for Type II DM patients. However, the pre-experimental design means that other unmeasured factors concurrent with the DFE intervention could potentially contribute to the observed improvements. To strengthen the evidence and establish a more robust causal link, future research should ideally incorporate a randomized controlled trial design, involve a larger and more diverse sample size, and include a longer follow-up period to assess the sustainability and long-term effects of DFE. Further investigation into the specific physiological mechanisms through which DFE impacts neuropathy would also add significant depth to the understanding of its therapeutic benefits. Despite these considerations, this study provides encouraging preliminary evidence for the utility of DFE in the comprehensive management of diabetic neuropathy.

Full Text

Comments

You need to be logged in to post a comment.